Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
650 studies found for:    "Anemia, Hemolytic, Congenital"
Show Display Options
Rank Status Study
1 Recruiting Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
Conditions: Congenital Hemolytic Anemia;   Diamond-Blackfan Anemia
Interventions: Procedure: Radiotherapy;   Drug: Alemtuzumab (Campath );   Drug: Sirolimus (Rapamune )
2 Active, not recruiting A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency
Condition: Pyruvate Kinase Deficiency
Intervention: Drug: AG-348
3 Completed Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
Conditions: Anemia, Sickle Cell;   Hematologic Diseases;   Hemoglobinopathies
Intervention: Drug: hydroxyurea
4 Completed Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
Conditions: Anemia, Sickle Cell;   Hematologic Diseases;   Hemoglobinopathies
Intervention: Drug: hydroxyurea
5 Recruiting Pyruvate Kinase Deficiency Natural History Study
Conditions: Pyruvate Kinase Deficiency;   Congenital Non-Spherocytic Hemolytic Anemia
Intervention:
6 Terminated The Dallas Hereditary Spherocytosis Cohort Study
Condition: Hereditary Spherocytosis
Intervention:
7 Recruiting Evaluation of the AMICUS RBCx System in Sickle Cell Patients
Condition: Sickle Cell Anemia
Intervention: Device: Amicus Red Cell Exchange in SCD patients
8 Completed Induction of Stable Chimerism for Sickle Cell Anemia
Conditions: Blood Disease;   Hematopoietic Stem Cell Transplantation;   Anemia, Sickle Cell
Interventions: Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Immunosuppression
9 Completed Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Conditions: Hematologic Diseases;   Anemia, Sickle Cell;   Beta-Thalassemia;   Hematopoietic Stem Cell Transplantation
Interventions: Drug: Sangstat;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Mycophenolate Mofetil;   Drug: Cyclosporine;   Procedure: Cord Blood Transplantation
10 Completed Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
Conditions: Hematologic Diseases;   Anemia, Sickle Cell
Interventions: Drug: Hydroxyurea;   Drug: Placebo
11 Recruiting The Congenital Dyserythropoietic Anemia Registry (CDAR)
Condition: Congenital Dyserythropoietic Anemia (CDA)
Intervention:
12 Recruiting Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
Conditions: Metabolism, Inborn Errors;   Lipid Metabolism, Inborn Errors;   Carbohydrate Metabolism, Inborn Errors;   Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV);   Carnitine Palmitoyl Transferase 2 Deficiency;   VLCAD Deficiency;   Medium-chain Acyl-CoA Dehydrogenase Deficiency;   Multiple Acyl-CoA Dehydrogenase Deficiency;   Carnitine Transporter Deficiency;   Neutral Lipid Storage Disease;   Glycogen Storage Disease Type II;   Glycogen Storage Disease Type III;   Glycogen Storage Disease Type IV;   Glycogen Storage Disease Type V;   Muscle Phosphofructokinase Deficiency;   Phosphoglucomutase 1 Deficiency;   Phosphoglycerate Mutase Deficiency;   Phosphoglycerate Kinase Deficiency;   Phosphorylase Kinase Deficiency;   Beta Enolase Deficiency;   Lactate Dehydrogenase Deficiency;   Glycogen Synthase Deficiency
Intervention: Other: Sugar
13 Recruiting Fetal Hemoglobin Induction Treatment Metformin
Conditions: Sickle Cell Anemia;   Sickle Cell Disease;   Hemoglobin Disorder;   Hemoglobin Disease; Sickle-Cell, Thalassemia
Intervention: Drug: Metformin
14 Enrolling by invitation Long-term Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy
Conditions: Beta-Thalassemia;   Sickle Cell Disease
Intervention: Other: Safety and efficacy assessments
15 Recruiting Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies
Conditions: Sickle Cell Disease;   Thalassemia
Intervention: Biological: CordIn
16 Recruiting HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Conditions: Sickle Cell Disease;   Beta Thalassemia-Major
Interventions: Drug: alemtuzumab (Campath IH);   Drug: Fludarabine;   Drug: Melphalan;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: Tacrolimus;   Biological: Hematopoietic Stem Cell Transplantation
17 Recruiting Sickle Cell Hemoglobinopathies and Bone Health
Conditions: Sickle Cell Disease;   Sickle Cell Trait
Interventions: Other: Healthy volunteers without SCT;   Other: Healthy volunteers with SCT;   Other: Volunteers with SCD
18 Recruiting Non-Myeloablative Conditioning and Bone Marrow Transplantation
Conditions: Sickle Cell Disease;   Hemoglobinopathies
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
19 Unknown  Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC
Condition: CDA Type I
Intervention: Drug: omeprazole
20 Completed Demographic, Clinical and Laboratory Characteristics of Children With Alpha Thalassemia in Northern Israel
Conditions: Thalassemia Alpha;   Hemolytic Anemia
Intervention: Other: Medical records summary

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.